Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Mark Offer"'
Autor:
Sajitha Sachchithanantham, Mark Offer, Christopher Venner, Shameem A. Mahmood, Darren Foard, Lisa Rannigan, Thirusha Lane, Julian D. Gillmore, Helen J. Lachmann, Philip N. Hawkins, Ashutosh D. Wechalekar
Publikováno v:
Haematologica, Vol 100, Iss 11 (2015)
Systemic AL amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly but treatment and outcomes have not been systematically studied in this group of patients in whom comorbidities and frailty ma
Externí odkaz:
https://doaj.org/article/e015c828565d41a29d14d50fa9dc59b8
Publikováno v:
Haematologica, Vol 93, Iss 2 (2008)
We report preliminary observations on the efficacy of bortezomib in 20 patients with AL amyloidosis whose clonal disease was active despite treatment with a median of 3 lines of prior chemotherapy, including a thalidomide combination in all cases. Pa
Externí odkaz:
https://doaj.org/article/09b94b392a0f45149ae845c14e4cdda1
Autor:
Grant Vallance, Bhuvan Kishore, Rebecca Robinson, Kevin Boyd, Moez Dungarwalla, Gurvin Chander, Karthik Ramasamy, Robin Aitchison, Matthew W Jenner, Jaimal Kothari, Sarah Bird, Zara Bhatti, Freya Collings, Nadjoua Maouche, Andy Peniket, Mark Offer, Ceri Bygrave
Publikováno v:
Leukemialymphoma. 62(6)
There are limited real world data on ixazomib, lenalidomide, and dexamethasone (IRd) in multiply relapsed myeloma. We analyzed outcomes of 116 patients who received IRd predominantly at second and subsequent relapse including those refractory to prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6ef559e033857657b894901ed0b7f5f
https://pubmed.ncbi.nlm.nih.gov/33356703
https://pubmed.ncbi.nlm.nih.gov/33356703
Autor:
Grant Vallance, Karthik Ramasamy, Jaimal Kothari, Julia Wolf, Huben Hubenov, Sally Moore, Mark Offer, Faouzi Djebbari, Eleni Louka, Pratap Neelakantan, Akhil Khera
Publikováno v:
British Journal of Haematology. 188
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5e875bbf7d6d9d921cfef56c625a710
https://doi.org/10.1111/bjh.16324
https://doi.org/10.1111/bjh.16324
Autor:
Philip N. Hawkins, Julian D. Gillmore, David J. Millar, Mark Offer, Aviva Petrie, Glenys A. Tennent, Helen J. Lachmann, Hugh J. B. Goodman, Winston L. Hutchinson, Janet Ruth Gallimore, Mark B. Pepys
Publikováno v:
British Journal of Haematology. 148:760-767
Serum amyloid P component (SAP) is a universal constituent of amyloid deposits and contributes to their formation and/or persistence. We therefore developed CPHPC ((R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexa-noyl]pyrrolidine-2 carboxylic acid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d747141f5b3623811830f5a8b95c40a8
https://doi.org/10.1111/j.1365-2141.2009.08036.x
https://doi.org/10.1111/j.1365-2141.2009.08036.x
Autor:
Christopher P. Venner, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, Philip N. Hawkins, Thirusha Lane, Lisa Rannigan, Sajitha Sachchithanantham, Mark Offer, Darren Foard, Ashutosh D. Wechalekar
Systemic AL amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly but treatment and outcomes have not been systematically studied in this group of patients in whom comorbidities and frailty ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e088ead7ad5a2a399068ea0120bba76
https://europepmc.org/articles/PMC4825311/
https://europepmc.org/articles/PMC4825311/
Publikováno v:
British journal of hospital medicine (London, England : 2005). 76(2)
Serological screening tests for multiple myeloma are commonly requested by physicians in both primary and secondary care to investigate patients presenting with anaemia or renal impairment of unknown cause. This article reviews the interpretation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c127c432e122106f85f7caaffd18fe1
https://pubmed.ncbi.nlm.nih.gov/25671472
https://pubmed.ncbi.nlm.nih.gov/25671472
Publikováno v:
Haematologica. 93(2)
We report preliminary observations on the efficacy of bortezomib in 20 patients with AL amyloidosis whose clonal disease was active despite treatment with a median of 3 lines of prior chemotherapy, including a thalidomide combination in all cases. Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec8e598aa4cee7565511f32945a640aa
https://pubmed.ncbi.nlm.nih.gov/18245653
https://pubmed.ncbi.nlm.nih.gov/18245653
Publikováno v:
Nature clinical practice. Cardiovascular medicine. 6(2)
Treatment of patients with amyloidosis is centered on reducing the supply of the respective amyloid fibril precursor protein. This Case Study describes a patient with cardiac acquired monoclonal immunoglobulin-light-chain amyloidosis, who also has an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6b63fba4e1e2067ef2c53edf8673b00
https://pubmed.ncbi.nlm.nih.gov/19079367
https://pubmed.ncbi.nlm.nih.gov/19079367
Autor:
Hugh J. B. Goodman, Ashutosh D. Wechalekar, Julian D. Gillmore, Mark Offer, Helen J. Lachmann, Philip N. Hawkins
Publikováno v:
Blood. 109(2)
High-dose melphalan with stem-cell transplantation is believed to be the most effective treatment for systemic light-chain (AL) amyloidosis, but many patients are ineligible because of the extent of their disease, and treatment-related mortality (TRM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::037b777809ceb617bc77d9b55f9c89c7
https://pubmed.ncbi.nlm.nih.gov/16990593
https://pubmed.ncbi.nlm.nih.gov/16990593